HER2 Heterogeneity in Gastric Cancer: A Comparative Study, Using Two Commercial Antibodies

Abstract EN

Background.

Although amplification of the gene encoding human epidermal growth factor receptor 2 (HER2) is used as an indicator for response to trastuzumab, the reported response rate is low, and few patients with gastric cancer (GC) benefit from this individualized therapy.

The aim of this study was to examine the expression of c-erbB-2 oncoprotein (HER2), in GC samples, using two commercial immunohistochemical (IHC) antibodies, and to validate the results by checking HER2 gene amplification by fluorescence in situ hybridization (FISH).

Methods.

We assessed the IHC expression of HER2 using the polyclonal antibody from Dako and CB11 clone from Leica, in 93 consecutive cases of GC samples.

In all of the cases, FISH analysis was also performed using the BOND-MAX platform.

Results.

No significant difference was observed between the two HER2 antibodies.

Of the 93 cases, 22.58% demonstrated at least focal and 1+ HER2 positivity.

Seven cases (7.53%) exhibited 3+ expression, and another 7 carcinomas (7.53%) were equivocal (2+).

HER2 amplification was seen in 11 cases (11.83%), 10 of which were differentiated adenocarcinomas.

In 5 of the cases, 2–5 sections were examined, which proved the extremely high intratumorally/intraglandular heterogeneity.

FISH heterogeneity was higher in cases with only 2+ positivity on IHC assessment, compared with those showing at least one small focus of 3+ overexpression.

HER2 amplification proved to be an independent negative prognostic factor.

Conclusions.

Due to the highly heterogeneous aspect of GC, at least 3-4 slides should be assessed by IHC, before considering a tumor to be HER2-negative.

In cases with small 3+ foci representing less than 5% of tumor and in equivocal (2+) cases, FISH analysis remains the gold standard method.